• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

    6/30/22 8:00:00 AM ET
    $NMRD
    Medical/Dental Instruments
    Health Care
    Get the next $NMRD alert in real time by email

    Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

    Corporate Highlights for FY2022:

    • Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a leading professional publication and direct to consumer via national papers with daily circulation exceeding 1.2 million
    • Recognized $503,906 in revenue for the fiscal year ending March 31, 2022
    • Signed a global commercial contract with MySugarWatch DuoPack Limited. Under terms of the deal, the Nemaura's CGMs and sensors will be provided as Duo-Packs with prescription-only medicines that are widely prescribed for people with Type 2 diabetes. The initial Duo-Pack presentation will be launched as the first of these medicines loses its patent protection in the UK in the calendar fourth quarter of 2022. Over 2 million prescriptions are written for these medicines in the top 3 EU countries (by GDP) alone, representing a significant opportunity
    • Launched beta trials of a metabolic health program using a body-worn glucose sensor along with an AI mobile application, intended for employers and insurers as well as direct to consumer, as a form of wellness and preventative medicine platform
    • Tiger Partners Trading LLC, an investment advisor to Julian Robertson's Tiger Management family office, acquired a 3.1% equity stake in the Company in February 2022
    • Appointed Dr. Arash Ghadar as Chief Operating Officer. Dr. Ghadar has taken the lead in supporting the commercial supply of product to our current and future licensees and global distributors
    • Completed two FDA audits in relation to the Company's previous PMA submission and is continuing the dialogue with the FDA in relation to the PMA submission

    "On the heels of successfully commercializing sugarBEAT® in fiscal 2022 and recognizing our first revenue from our UK licensee MySugarWatch Limited, our primary goal in fiscal 2023 is to expand our revenue by supporting the launch effort of MySugarWatch Limited in the UK. We expect additional purchase orders to support the UK launch, as well as the anticipated Duo-Pack launch later in calendar 2022. MySugarWatch Limited has already begun mass advertising through education and awareness campaigns to healthcare professionals and direct to consumers through the national press," commented Dr. Faz Chowdhury, CEO of Nemaura.

    "Furthermore, we are exploring additional new channels in other territories with our technology platform. We have also started to engage with large scale manufacturers to enable us to meet the strong worldwide diabetic monitoring demand, and any appreciable scale we can build in our business should be meaningful to shareholder value. We look forward to updating investors with additional corporate highlights as they unfold," concluded Dr. Chowdhury.

    FY2022 Financial Summary:

    • The fiscal year ended March 31, 2022 marked a pivotal milestone for the Company, as it commenced deliveries of sugarBEAT® to MSWL pursuant to the initial order placed in April 2021
    • Research and development expenses were consistent with the prior year at approximately $1.5 million. The Company's historically more significant research and development expenses relating to clinical trials and improvements made to the sugarBEAT® device began to flatten out over the 2022 fiscal year
    • General and administrative expenses were $6,173,049 and $3,032,138 for the fiscal years ended March 31, 2022 and 2021, respectively. These expenses consisted of fees for legal, professional, consultancy, audit services, investor relations, insurance, advertising, and general and operational wages. The year-over-year increase in expenses were driven predominantly by increased wages, as the Company has increased headcount to support the operational scale-up process across both its UK and U.S. teams

    About Nemaura Medical, Inc.

    Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

    Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

    The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

    For more information, please visit www.NemauraMedical.com.

    Cautionary Statement Regarding Forward-Looking Statements:

    The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners' ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the "FDA") reserves the right to re-evaluate its decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical's filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.

    Contact:

    Jules Abraham

    CORE IR

    917-885-7378

    [email protected]

    NEMAURA MEDICAL INC.
    Consolidated Balance Sheet



      As of March 31,  As of March 31, 
      2022

    ($)
      2021

    ($)
     
           
    ASSETS        
    Current assets:        
    Cash  17,749,233   31,865,371 
    Prepaid expenses and other receivables  750,167   1,269,513 
    Accounts receivable – related party  101,297   - 
    Inventory  1,487,771   850,622 
    Total current assets  20,088,468   33,985,506 
             
    Other assets:        
    Property and equipment, net of accumulated depreciation  532,508   202,145 
    Intangible assets, net of accumulated amortization  1,480,980   1,055,256 
    Total other assets  2,013,488   1,257,401 
    Total assets  22,101,956   35,242,907 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities:        
    Accounts payable  136,310   253,694 
    Liability due to related parties  -   148,795 
    Other liabilities and accrued expenses  998,622   180,522 
    Notes payable, current portion  19,188,724   5,733,370 
    Deferred revenue  259,256   103,470 
    Total current liabilities  20,582,912   6,419,881 
             
    Non-current portion of notes payable  -   19,188,724 
    Non-current portion of deferred revenue  1,052,960   1,276,130 
    Total liabilities  21,635,872   26,884,735 
             
    Commitments and contingencies        
             
    Stockholders' equity:        
    Common stock, par value $0.001 - authorized: 42,000,000 shares; issued and outstanding: 24,102,866 and 22,941,157 as of March 31, 2022 and 2021, respectively  24,103   22,941 
    Additional paid-in capital  38,295,775   32,044,335 
    Accumulated deficit  (37,731,476)  (23,844,671)
    Accumulated other comprehensive (loss) income  (122,318)  135,567 
    Total stockholders' equity  466,084   8,358,172 
    Total liabilities and stockholders' equity  22,101,956   35,242,907 
             

    See notes to the consolidated financial statements.



    NEMAURA MEDICAL INC.
    Consolidated Statement of Operations and Comprehensive Loss



      Years Ended March 31, 
      2022

    ($)
      2021

    ($)
     
    Sales  503,906   - 
    Cost of Sales  (344,300)  - 
    Gross Profit  159,606   - 
    Operating expenses:        
    Research and development  1,556,988   1,554,603 
    General and administrative  6,173,049   3,032,138 
    Total operating expenses  7,730,037   4,586,741 
             
    Loss from operations  (7,570,431)  (4,586,741)
             
    Interest expense  (6,666,630)  (2,007,687)
    Loss before income tax benefit  (14,237,061)  (6,594,428)
             
    Provision for income tax benefit  350,256   335,832 
    Net loss  (13,886,805)  (6,258,596)
             
    Other comprehensive income:        
    Foreign currency translation adjustment  (257,885)  472,559 
    Comprehensive loss  (14,144,690)  (5,786,037)
             
    Net loss per share, basic and diluted $(0.59) $(0.28)
    Weighted average number of shares outstanding  23,383,758   22,283,377 

    See notes to the consolidated financial statements.

    NEMAURA MEDICAL INC.
    Consolidated Statement of Cash Flows



      Year Ended March 31, 
      2022

    ($)
      2021

    ($)
     
    Cash Flows from Operating Activities:        
    Net loss  (13,886,805)  (6,258,596)
             
    Adjustments to reconcile net loss to net cash used in operating activities:        
    Depreciation and amortization  229,810   98,075 
    Accretion of debt discount  6,666,630   2,007,687 
    Mark-to-market foreign exchange revaluation  440,196   - 
    Stock-based compensation  220,917   113,171 
             
    Changes in assets and liabilities:        
    Prepaid expenses and other receivables  519,346   (767,050)
    Inventory  (637,149)  (564,313)
    Accounts payable  (117,384)  (39,914)
    Accounts receivable – related party  (250,092)  (681,298)
    Other liabilities and accrued expenses  310,490   94,141 
    Net cash used in operating activities  (6,504,041)  (5,998,097)
             
    Cash Flows from Investing Activities:        
    Capitalized patent costs  (83,691)  (81,952)
    Purchase of property and equipment  (481,718)  (90,730)
    Capitalized software development costs  (391,073)  (663,758)
    Net cash used in investing activities  (956,482)  (836,440)
             
    Cash Flows from Financing Activities:        
    Proceeds from issuance of common stock  3,118,792   15,750,672 
    Costs incurred in relation to equity financing  (50,765)  (957,193)
    Proceeds from warrant exercise  2,963,658   400,503 
    Proceeds from issuance of notes payable  -   25,000,000 
    Debt issuance costs paid  -   (1,525,035)
    Repayments of notes payable  (12,400,000)  (600,000)
    Repayments of insurance financing  -   (82,555)
    Net cash (used in) provided by financing activities  (6,368,315)  37,986,392 
             
    Net (decrease) increase in cash  (13,828,838)  31,151,855 
    Effect of exchange rate changes on cash  (287,300)  607,409 
    Cash at beginning of year  31,865,371   106,107 
    Cash at end of year  17,749,233   31,865,371 
    Supplemental disclosure of non-cash financing activities:



     
            
    Prepayment of equity compensation  -  $50,000 
    Licenses acquired through stock issuance  -  $100,000 
    Monitoring fees added to notes payable $2,764,775  $718,661 
             

    See notes to the consolidated financial statements.



    Primary Logo

    Get the next $NMRD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NMRD

    DatePrice TargetRatingAnalyst
    3/29/2022$12.00Buy
    H.C. Wainwright
    12/2/2021$7.50Buy
    EF Hutton
    More analyst ratings

    $NMRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Ghadar-Ghadr Arash

      3 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:29:16 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Natha Salim

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      2/1/22 4:13:05 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Leadership Updates

    Live Leadership Updates

    See more
    • Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

      LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in

      9/26/23 9:50:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Dr. Arash Ghadar as Chief Operating Officer

      Loughborough, England, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. "Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily w

      1/10/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Samantha Sanders as Global Head of Digital Programs

      Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs. Samantha has over two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally.  Prior to joining the Nemaura team, more recently Samantha has bee

      4/15/21 8:07:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nemaura Medical with a new price target

      H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00

      3/29/22 7:19:31 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • EF Hutton initiated coverage on Nemaura Medical with a new price target

      EF Hutton initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $7.50

      12/2/21 8:50:25 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    SEC Filings

    See more
    • Nemaura Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nemaura Medical Inc. (0001602078) (Filer)

      9/26/24 9:21:38 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14C filed by Nemaura Medical Inc.

      DEF 14C - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:59:03 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by Nemaura Medical Inc.

      NT 10-K - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:00:02 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA

      WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ --   Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon

      4/11/24 10:00:00 AM ET
      $FUBO
      $HOUR
      $HTCR
      $MOBQ
      Movies/Entertainment
      Consumer Discretionary
      Catalog/Specialty Distribution
      EDP Services
    • Important Update on Listing Status and Strategic Direction

      Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our cont

      1/3/24 7:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

      Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision

      12/13/23 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Financials

    Live finance-specific insights

    See more
    • Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nemaura's CEO Dr. Faz Chowdhury discusses Nemaura's continuous glucose sensor, the sugarBEAT®, its potential impact on the 500

      11/4/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

      Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022. Corporate Highlights for FY2022: Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a

      6/30/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021

      Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022. Recent Corporate Highlights: Launched a digital healthcare subscription service in the U.S. under the brand name BEAT®diabetes, targeted at over 25 million people with Type 2 diabetes and 88 million people with pre-diabetes in the U.S.Received positive feedback fro

      8/16/21 8:30:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nemaura Medical Inc.

      SC 13G - Nemaura Medical Inc. (0001602078) (Subject)

      2/14/24 1:54:39 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care